|
|
||||||||
Department of Clinical Physiology, Huddinge University Hospital, S-141 86 Huddinge; and Department of Physiology and Division of Pharmacology, Karolinska Institute, S-171 77 Stockholm, Sweden
Received 10 April 1996; accepted in final form 24 January 1997.
Ahlborg, Gunvor, and Jan M. Lundberg. Nitric
oxide-endothelin-1 interaction in humans. J. Appl.
Physiol. 82(5): 1593-1600, 1997.
Healthy men
received NG-monomethyl-L-arginine
(L-NMMA) intravenously to study
cardiovascular and metabolic effects of nitric oxide synthase blockade
and whether this alters the response to endothelin-1 (ET-1) infusion.
Controls only received ET-1.
L-NMMA effects were that heart
rate (17%), cardiac output (17%), and splanchnic and renal blood flow
(both 33%) fell promptly (all P < 0.01). Mean arterial blood pressure (6%), and systemic (28%) and
pulmonary (40%) vascular resistances increased
(P < 0.05 to 0.001). Arterial ET-1
levels (21%) increased due to a pulmonary net ET-1 release
(P < 0.05 to 0.01). Splanchnic glucose output (SGO) fell (26%, P < 0.01). Arterial insulin and glucagon were unchanged. Subsequent ET-1
infusion caused no change in mean arterial pressure, heart rate, or
cardiac output, as found in the present controls, or in splanchnic and
renal blood flow or splanchnic glucose output as previously found with
ET-1 infusion (G. Ahlborg, E. Weitzberg, and J. M. Lundberg.
J. Appl. Physiol. 79: 141-145,
1995). In conclusion, L-NMMA
like ET-1, induces prolonged cardiovascular effects and suppresses SGO.
L-NMMA causes pulmonary ET-1
release and blocks responses to ET-1 infusion. The results indicate
that nitric oxide inhibits ET-1 production and thereby interacts with
ET-1 regarding increase in vascular tone and reduction of SGO in
humans.
NG-monomethyl-L-arginine and endothelin-1 infusion; cardiac output; splanchnic and renal blood flow; systemic and pulmonary vascular resistance; arterial levels and pulmonary release of endothelin-1; insulin and splanchnic glucose output
This article has been cited by other articles:
![]() |
N. Toda, K. Ayajiki, and T. Okamura Cerebral Blood Flow Regulation by Nitric Oxide: Recent Advances Pharmacol. Rev., March 1, 2009; 61(1): 62 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Lteif, A. D. Fulford, R. V. Considine, I. Gelfand, A. D. Baron, and K. J. Mather Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans Am J Physiol Endocrinol Metab, December 1, 2008; 295(6): E1510 - E1517. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Merkus, B. Houweling, V. J. de Beer, Z. Everon, and D. J. Duncker Alterations in endothelial control of the pulmonary circulation in exercising swine with secondary pulmonary hypertension after myocardial infarction J. Physiol., May 1, 2007; 580(3): 907 - 923. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lteif, P. Vaishnava, A. D. Baron, and K. J. Mather Endothelin Limits Insulin Action in Obese/Insulin-Resistant Humans Diabetes, March 1, 2007; 56(3): 728 - 734. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Mather, A. Lteif, H. O. Steinberg, and A. D. Baron Interactions Between Endothelin and Nitric Oxide in the Regulation of Vascular Tone in Obesity and Diabetes Diabetes, August 1, 2004; 53(8): 2060 - 2066. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. D. Wagner, S. Buz, C. Knosalla, R. Hetzer, and B. Hocher Modulation of Circulating Endothelin-1 and Big Endothelin by Nitric Oxide Inhalation Following Left Ventricular Assist Device Implantation Circulation, September 9, 2003; 108(90101): II-278 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Toda and T. Okamura The Pharmacology of Nitric Oxide in the Peripheral Nervous System of Blood Vessels Pharmacol. Rev., June 1, 2003; 55(2): 271 - 324. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ahlborg and J. Lindstrom Insulin sensitivity and big ET-1 conversion to ET-1 after ETA- or ETB-receptor blockade in humans J Appl Physiol, December 1, 2002; 93(6): 2112 - 2121. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. King-VanVlack, J. D. Mewburn, C. K. Chapler, and P. H. MacDonald Endothelial modulation of skeletal muscle blood flow and VO2 during low- and high-intensity contractions J Appl Physiol, February 1, 2002; 92(2): 461 - 468. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-F. Chou, M.-S. Wu, C.-T. Chien, C.-C. Yu, and C.-F. Chen Enhanced expression of nitric oxide synthase in the early stage after increased pulmonary blood flow in rats Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 331 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Montanari, N. Carra, P. Perinotto, V. Iori, E. Fasoli, A. Biggi, and A. Novarini Renal Hemodynamic Control by Endothelin and Nitric Oxide Under Angiotensin II Blockade in Man Hypertension, February 1, 2002; 39(2): 715 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Montanari, A. Biggi, N. Carra, E. Fasoli, M. Calzolari, F. Corsini, P. Perinotto, and A. Novarini Endothelin-A Blockade Attenuates Systemic and Renal Hemodynamic Effects of L-NAME in Humans Hypertension, January 1, 2000; 35(1): 518 - 523. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. M. Best, L. O. Lerman, J. C. Romero, D. Richardson, D. R. Holmes Jr, and A. Lerman Coronary Endothelial Function Is Preserved With Chronic Endothelin Receptor Antagonism in Experimental Hypercholesterolemia In Vitro Arterioscler Thromb Vasc Biol, November 1, 1999; 19(11): 2769 - 2775. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Mundhenke, B Schwartzkopff, M Köstering, U Deska, R M Klein, and B E Strauer Endogenous plasma endothelin concentrations and coronary circulation in patients with mild dilated cardiomyopathy Heart, March 1, 1999; 81(3): 278 - 284. [Abstract] [Full Text] |
||||
![]() |
J. A. M. Avontuur, F. Boomsma, A. H. van den Meiracker, F. H. de Jong, and H. A. Bruining Endothelin-1 and Blood Pressure After Inhibition of Nitric Oxide Synthesis in Human Septic Shock Circulation, January 19, 1999; 99(2): 271 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Broere, A. H. Van Den Meiracker, F. Boomsma, F. H. M. Derkx, A. J. Man In'T Veld, and M. A. D. H. Schalekamp Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME Am J Physiol Renal Physiol, December 1, 1998; 275(6): F870 - F877. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ahlborg and J. M. Lundberg Cyclooxygenase inhibition potentiates the renal vascular response to endothelin-1 in humans J Appl Physiol, November 1, 1998; 85(5): 1661 - 1666. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |